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Aims. To assess whether circulating 25-hydroxyvitamin D3 (25OHD) and mineral metabolism-related factors (serum phosphate,
calcium, and parathormone) are associated with subclinical carotid atherosclerosis (SCA), deﬁned as the presence of carotid
atherosclerotic plaques (main study outcome), in patients with type 2 diabetes mellitus (T2DM) without kidney disease or
previous cardiovascular disease. Methods. We undertook a post hoc analysis of a cross-sectional study in adults with
T2DM in whom we evaluated SCA. A total of 303 subjects with T2DM were included. Clinical variables and carotid
ultrasound imaging were obtained. Results. We found no association of 25OHD with the presence of SCA. However,
calcium phosphate (CaP; mg2/dL2) product was positively associated with the presence of carotid plaques (ORadj = 1.078;
95% CI: 1.017–1.142). An inverse association was observed between higher levels of 25OHD (≥30 ng/mL versus <20 ng/mL
concentrations) and common carotid intima-media thickness (cIMT; mm) (βadj± SE =−0.055± 0.024). We conclude that the
CaP product is independently associated with the presence of established subclinical carotid atherosclerosis in patients with T2DM.
1. Introduction
Patients with type 2 diabetes mellitus (T2DM) are at 2- to
4-fold higher risk of cardiovascular mortality compared
with nondiabetic subjects [1]. Further, type 2 diabetic
subjects will lose 16–18 quality-adjusted life-years due to
diabetes and will die approximately 6 years earlier than the
nondiabetic population [2, 3]. T2DM and atherosclerosis
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share almost all the traditionally recognized main common
risk factors: obesity, high blood pressure, dyslipidemia,
dietary factors, sedentary lifestyle, and age. Diabetic ath-
erosclerosis develops earlier and has a more extensive
and diﬀuse presentation than atherosclerosis in nondia-
betic subjects [4]. Early lesions in several arterial territories
(i.e., plaques) can be identiﬁed in atherosclerosis. There is
an increased burden of atherosclerotic plaques in patients
with T2DM well before the appearance of cardiovascular
events [5, 6]. Further, the presence of carotid plaques is
a stronger predictor of future events than carotid intima-
media thickness [7]. Additionally, in type 2 diabetic sub-
jects, the presence of carotid plaques strongly predicts
future cardiovascular events [6]. Nevertheless, clinical pre-
diction of cardiovascular disease in type 2 diabetes is still
an important challenge. Unfortunately, additional bio-
markers for improving cardiovascular risk prediction have
not yet been proved to be helpful in the clinical setting
[8]. Thus, the identiﬁcation of new biomarkers applicable
to clinical practice is a current challenge to improve risk
evaluation and clinical outcomes.
The contribution of diﬀerent factors involved in the reg-
ulation of mineral metabolism in the pathogenesis of athero-
sclerosis and subsequent cardiovascular events is supported
by experimental and clinical evidence [9–11]. Among these
factors, vitamin D is probably the most extensively studied
one. Vitamin D is a hormone that is instrumental in main-
taining mineral homeostasis, bone mineralization, and regu-
lation of parathyroid hormone secretion [9]. Although its
active form is 1,25-hydroxyvitamin D3, the circulating con-
centrations of 25-hydroxyvitamin D3 (25OHD) is the param-
eter that indicates the vitamin D deﬁciency/suﬃciency status.
Evidence from some association studies pointed to an associ-
ation of vitamin D deﬁciency with subclinical atherosclerosis
or established cardiovascular disease [10, 12, 13]. Also,
cohort studies found that lower vitamin D levels were predic-
tive of cardiovascular morbidity and mortality [14]. How-
ever, in other recent well-designed cohort studies, vitamin
D was not found to be associated with subclinical atheroscle-
rosis and its progression [15].
Although calcium and phosphate homeostasis is tightly
regulated by vitamin D and parathormone (PTH), less
attention has been paid to their potential involvement in
the pathogenesis of atherosclerosis or as predictors of car-
diovascular disease. Elevated concentrations of calcium and
phosphate have also been related to the development of
atherosclerosis and cardiovascular events [16–22]. How-
ever, not all studies addressing the role of vitamin D in
the development of atherosclerosis included simultaneously
the determination of calcium and phosphate or their inclu-
sion in their prediction or association models.
Considering all the evidence described above, we
hypothesized that vitamin D and other markers of mineral
metabolism are associated with the presence of carotid
atherosclerotic plaques in patients with T2DM free from
established chronic kidney disease and cardiovascular dis-
ease. Thus, the aim of this study was to test whether circulat-
ing vitamin D and other mineral metabolism-related factors,
that is, calcium, phosphate, and intact parathormone, are
associated with the presence of subclinical carotid atheroscle-
rosis in type 2 diabetes mellitus patients.
2. Methods
2.1. Study Design and Subjects. This is an ancillary study of a
previous cross-sectional study in adult type 2 diabetic
patients recruited at a single reference hospital in Catalonia,
Spain. The primary objective of the current approach was
to assess the potential association between subclinical athero-
sclerosis and 25OHD and other mineral metabolism factors:
calcium, phosphate, and PTH. The study population has
been recently described in the previous study that was
designed to assess subclinical carotid atherosclerosis and
cerebral microvascular disease in patients with T2DM
[5, 23]. A total of 303 subjects with (n = 180) or without
(n = 123) subclinical atherosclerosis were included on the
basis of availability of serum samples. The inclusion criteria
were age from 40 to 75 years old, normal renal function
(estimated glomerular ﬁltration rate (eGFR)> 60mL/min),
and availability of the main study variables to perform the
study assessments. The variables that were considered for
this substudy were weight, height, waist, smoking habit, pres-
ence of dyslipidemia and hypertension, duration of diabetes
and its treatment, lipid proﬁle, age, sex, ethnicity, and the
carotid ultrasound parameters.
The exclusion criteria were deﬁned as follows: estab-
lished chronic kidney disease (deﬁned as either albumin/
creatinine> 300mg/g and/or eGFR< 60mL/min), previous
supplementation with vitamin D and/or calcium, and pre-
viously known cardiovascular disease events or associated
revascularization procedures, including coronary heart dis-
ease, cerebrovascular disease, or peripheral vascular disease
(this included the diagnosis of diabetic foot disease). For
this purpose, the patients’ clinical records were thoroughly
reviewed in addition to the anamnestic evaluation and
physical examination.
A detailed description of the study subjects and clinical
procedures is provided elsewhere [5]. Out of 312 subjects of
the original study, 9 participants were ﬁnally excluded: 4
patients were taking oral vitamin D and/or calcium supple-
ments, and 5 other patients had no samples for the determi-
nation the main lab study variables. A total of 18 patients did
not have data on physical activity and dietary intake ques-
tionnaires. The study protocol was approved by the Ethics
Committee of University Hospital Arnau de Vilanova, and
all participants signed a written consent form.
2.2. Clinical and Laboratory Procedures. Relevant demo-
graphic and clinical data were obtained from each subject.
Weight, height, and waist circumference were measured
using standardized clinical procedures. Patients were clas-
siﬁed as having hypertension or dyslipidemia when they
were receiving antihypertensive or lipid-lowering treatment,
respectively. Laboratory variables were determined in fasting
blood and spot urine samples. All analytical tests were per-
formed using standard laboratory methods. Basic blood and
urine biochemistry were determined using a Hitachi Modu-
lar DDPP analyzer (Roche Diagnostics, Indianapolis, USA).
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Hemoglobin A1c was measured using an HPLC Variant II
Turbo (Bio-RAD, Hercules, USA). Intact parathormone
was measured in an Elecsys E170 analyzer (Roche Diag-
nostics, Indianapolis, USA) by electrochemiluminescence
immunoassay with 2.2% and 6% intra- and interassay vari-
ability, respectively. Serum 25OHD concentrations were
measured using an Architect i2000SR analyzer (Abbott Diag-
nostics, Lake Forest, USA) by a chemiluminescent micropar-
ticle immunoassay with an intra- and interassay variability
values of 2.3% and 6.2%, respectively. Vitamin D deﬁciency
was deﬁned as a concentration of 25OHD below 20ng/mL,
and vitamin D insuﬃciency as values between 20 and
<30 ng/mL, as deﬁned by the Endocrine Society [24]. These
thresholds were used also for the analyses of the study. Die-
tary intake of vitamin D and calcium was evaluated using a
101-food-item semiquantitative food frequency validated
questionnaire (available at http://bibliodieta.umh.es/ﬁles/
2011/07/CFA101.pdf) [25], and the dietary content of
vitamin D and calcium was calculated using the food compo-
sition tables of the US Department of Agriculture and sup-
plemented with Spanish sources [25, 26]. The season of
assessment was classiﬁed according to the following distri-
bution: winter (January–March), spring (April–June), sum-
mer (July–September), and autumn (October–December),
according to the date of blood sampling. Physical activity
was categorized as sedentary and active deﬁning sedentary
subjects as those expending less than 10% of their daily
energy expenditure in activities using 4 or more basal metab-
olism rate multiples (equal or greater physical activity expen-
diture than brisk walking for 30 minutes) [27].
2.3. Carotid Ultrasound Imaging Procedures. Subclinical
carotid atherosclerosis (SCA) was deﬁned as the presence of
any atherosclerotic plaque in the carotid arteries. All partici-
pants underwent the same carotid ultrasound protocol per-
formed by the same researcher, who was blinded to the
characteristics of the study participants. Ultrasound images
were obtained with a Siemens Sequoia 512 and a 15MHz lin-
ear array probe. To identify the presence of plaques a 2D-
mode and colour Doppler imaging, techniques were likewise
used in longitudinal and transverse planes. The common
carotid intima-media thickness (cIMT) was determined
using conventional ultrasound procedures as measured from
the media-adventitia interface to the intima-lumen interface.
The intraobserver variability of the IMT image reading,
calculated as the intraclass correlation coeﬃcient, of the
researcher performing this procedure is 0.93 (95% conﬁ-
dence interval: 0.89–0.98). According to the Mannheim
consensus [28], plaque was deﬁned as a focal structure
encroaching into the arterial lumen at least 0.5mm or 50%
of the surrounding cIMT value or that demonstrates a thick-
ness> 1.5mm. A detailed description of the ultrasound pro-
cedures used in this study has been recently described [5, 29].
2.4. Statistical Analysis. Quantitative variables were summa-
rized using mean and standard deviation for those normally
distributed (according to Shapiro-Wilks test) and as median
and interquartile intervals otherwise. Qualitative variables
were summarized using absolute and relative frequencies.
For the variables showing a nonlinear relationship with any
speciﬁc study outcome, some recoding options were tested.
The relationship between potential risk factors and subclini-
cal atherosclerosis was analyzed by adjusting multivariable
logistic regression models for the presence of any plaque
and by adjusting multivariable linear regression models for
the common intima-media thickness. Logistic regression
model building process was started by a bivariate analysis
consisting of the chi-squared or McNemar tests that were
used to compare qualitative variables and the t-test or
Mann–Whitney U test that were used to compare quantita-
tive variables (normally distributed or not, resp.) between
two groups. A ﬁrst multivariable logistic regression model
was adjusted with all the clinically signiﬁcant variables. The
model was reduced by dropping one variable in each step,
starting by the one with the highest nonsigniﬁcant p-value
according to the likelihood ratio test (LRT). Calibration
and discrimination for the ﬁnal proposed logistic regression
models were assessed by the Hosmer-Lemeshow goodness-
of-ﬁt test and the AUC. For the ﬁnal linear regression model,
the Kolmogorov-Smirnov goodness-of-ﬁt test was performed
and the coeﬃcient of determination was provided. Adjusted
association measures were the odds ratio (OR) and their
95% conﬁdence interval (95% CI) with logistic regression
models and eﬀect (β) and standard error (±SE) with linear
regression. The open source statistical analysis software
package R [30] and a statistical signiﬁcance level of p < 0 05
were used.
3. Results
Clinical and biochemical characteristics of patients with
T2DM according to their SCA status are shown in Table 1.
In the group of subjects with dyslipidemia, 130 (92.9%)
patients were receiving treatment with statins (84 with and
46 without carotid plaques). Among patients with carotid
plaques (i.e., SCA), 81 had only 1 plaque and 99 had 2 or
more carotid plaques. As expected, subjects with SCA
showed also increased values of common carotid intima-
media thickness, which is an early measure of subclinical
carotid atherosclerosis (0.83 versus 0.73mm; p < 0 001).
Subjects with SCA were also older than those without SCA
(62.0 versus 57.0 years; p < 0 001). Hypertension was more
frequent in patients with SCA (64.2% versus 46.3%;
p = 0 003), and also, as expected, they had higher systolic
blood pressure (142 versus 136mmHg; p = 0 003). However,
the study groups were similar in terms of BMI, waist circum-
ference, physical activity, frequency of dyslipidemia,
diabetes-related characteristics (insulin treatment, glycated
hemoglobin, or diabetes duration), and lipid proﬁle.
There were no diﬀerences in 25OHD concentrations
between the 2 study groups (18.4 versus 18.8 ng/mL;
p = 0 341). Although serum calcium was similar in both
groups, serum phosphate was higher in patients with SCA
(3.57 versus 3.41mg/dL; p = 0 026). The calcium phosphate
(CaP) product was also increased in subjects with SCA
(32.9 versus 31.9mg2/dL2; p = 0 026). Additionally, PTH
concentrations were lower in patients with SCA (42.4 versus
47.1 pg/mL; p = 0 027). Finally, there were no diﬀerences in
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terms of dietary calcium or vitamin D intake between groups.
The multivariable analysis showed that there were no sig-
niﬁcant associations between female sex, 25OHD and PTH
concentrations, and subclinical atherosclerosis (Table 2).
However, age (OR=1.055; 95% CI=1.027–1.084; p < 0 001)
and systolic blood pressure (OR=1.016; 95% CI= 1.002–
1.030; p = 0 028) were positively associated with the presence
of carotid plaques (Table 2). Although 25OHD and PTH
were not associated with the presence of plaques, we found
a positive association between the CaP product and the
presence of SCA (OR=1.078; 95% CI=1.017–1.142;
p = 0 012) (Table 2).
Thereafter, a multivariable analysis for cIMT was also
performed (Table 3). A basic age- and sex-adjusted model
and the fully adjusted model are shown in Supplementary
Table 1 available online at https://doi.org/10.1155/2017/
3498368. Vitamin D≥ 30ng/mL, as compared to vitamin
D< 20 ng/mL, was associated with lower common cIMT
(β± SE=−0.055± 0.024; p = 0 023). Age (β± SE=0.005
± 0.0008; p < 0 001) and the presence of dyslipidemia
Table 1: Clinical and biochemical characteristics of patients with type 2 diabetes with and without subclinical carotid atherosclerosis (SCA).
No SCA n = 123 SCA n = 180 p value
Age (years) 57.0 [48.0; 64.0] 62.0 [54.0; 69.0] <0.001
Female sex 66 (53.7) 83 (46.1) 0.241
Caucasian 114 (92.7) 175 (97.2) 0.116
Current smoking 20 (16.3) 40 (22.2) 0.258
Physical activity (minutes) 60 (50.8) 80 (47.6) 0.676
Hypertension 57 (46.3) 115 (64.2) 0.003
Systolic blood pressure (mmHg) 136± 17.1 142± 19.6 0.003
Diastolic blood pressure (mmHg) 77.5± 10.6 76.6± 10.9 0.504
Dyslipidemia 51 (41.5) 89 (49.7) 0.195
Insulin treatment 39 (31.7) 62 (34.4) 0.710
Disease duration (years) 7.00 [4.00; 12.5] 8.50 [4.00; 15.0] 0.195
Body mass index (kg/m2) 30.6 [28.3; 34.7] 30.6 [27.7; 34.4] 0.280
Waist circumference (cm) 105± 11.8 105± 10.9 0.903
Season
0.690
Spring 30 (24.4) 53 (29.4)
Summer 44 (35.8) 59 (32.8)
Autumn 32 (26.0) 40 (22.2)
Winter 17 (13.8) 28 (15.6)
HbA1c (%) 7.55 [6.60; 8.60] 7.60 [6.90; 8.40] 0.970
Total cholesterol (mg/dL) 183 [162; 210] 182 [164; 204] 0.969
HDL-c (mg/dL) 46.0 [40.0; 57.0] 49.0 [42.0; 60.0] 0.065
LDL-c (mg/dL) 107 [86.8; 130] 107 [89.2; 127] 0.919
Triglycerides (mg/dL) 122 [85.0; 181] 110 [82.8; 155] 0.105
Serum creatinine (mg/dL) 0.77 [0.67; 0.90] 0.80 [0.69; 0.93] 0.480
Urinary albumin/creatinine ratio (mg/g) 7.10 [3.60; 15.5] 8.43 [3.97; 20.3] 0.318
25OHD (ng/mL) 18.8 [13.2; 26.2] 18.4 [13.3; 24.2] 0.341
Vitamin D levels
0.530
<20 ng/mL 65 (52.8) 106 (58.9)
20–<30 ng/mL 42 (34.1) 56 (31.1)
≥30 ng/mL 16 (13.0) 18 (10.0)
Dietary vitamin D intake (μg/day) 4.47 [2.93; 5.70] 3.88 [2.92; 5.05] 0.181
Dietary calcium intake (mg/day) 1182 [866; 1467] 1116 [811; 1379] 0.155
Parathormone (pg/mL) 47.1 [36.8; 56.6] 42.4 [33.9; 52.3] 0.027
Calcium (mg/dL) 9.25 [9.01; 9.42] 9.29 [9.06; 9.48] 0.312
Phosphate (mg/dL) 3.41 [3.13; 3.76] 3.57 [3.28; 3.84] 0.026
Calcium phosphate product (mg2/dL2) 31.9 [29.0; 35.2] 32.9 [30.3; 36.2] 0.026
cIMT (mm) 0.73 [0.66; 0.80] 0.83 [0.73; 0.91] <0.001
Values are mean ± SD, n (%) or median [interquartile range]. HbA1c: glycated hemoglobin; HDL-c: high-density lipoprotein cholesterol; LDL-c; low-density
lipoprotein cholesterol; 25OHD: 25-hydroxyvitamin D3, cIMT: common carotid intima-media thickness.
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(β± SE=0.042± 0.015; p = 0 006) were positively associ-
ated with common carotid intima-media thickness. There
was a negative association between female sex and cIMT
(β± SE=−0.05± 0.02; p = 0 002). The age- and sex-adjusted
model and the fully adjusted model are shown in Supple-
mentary Table 2.
4. Discussion
In this study, we aimed to investigate the relationship
between 25OHD and other mineral metabolism-related fac-
tors and the presence of subclinical carotid atherosclerosis,
assessed by the presence of carotid plaques, in type 2 diabetic
subjects. The study participants were free from chronic
kidney disease without previous cardiovascular disease.
Our results clearly show that increasing values of calcium
phosphate product are associated with the presence of ath-
erosclerotic carotid plaques. Concentrations of 25OHD in
the higher range were negatively associated with lower cIMT
in these subjects.
Existing experimental and clinical evidence points to the
involvement of phosphate and calcium in the development of
atherosclerosis [18, 20]. Most of the evidence in this ﬁeld is
restricted to the study of the role of mineral metabolism in
chronic kidney failure. Actually, phosphate has been shown
to be associated with subclinical atherosclerosis in patients
with advanced kidney disease [31]. The dysregulation of
mineral metabolism induced by hyperphosphatemia accom-
panying the impairment of kidney function is considered one
of the main drivers of increased cardiovascular disease in
these patients [18]. Diﬀerent pieces of evidence point to
CaP product as a potential marker of future cardiovascu-
lar events. Most of the studies addressing this issue have
been performed in patients with chronic kidney disease
[17, 21, 22]. CaP product is a marker of adverse outcomes
in patients with peripheral artery disease under hemodialysis
[17]. Additionally, future mortality in patients receiving
chronic dialysis is also predicted by CaP product [22]. Fur-
ther, a recent study in young subjects with chronic kidney
disease showed a clear positive association of CaP product
and ﬁbroblast growth factor 23 (FGF-23) [21]; the latter is
involved in vascular calciﬁcation and is associated with
future cardiovascular morbidity and mortality in patients
with renal insuﬃciency [18, 20].
Very few additional studies were done in subjects without
chronic kidney disease [16, 19]. A very well-known
community-based epidemiological study of cardiovascular
disease in the US showed that calcium, phosphate, and
CaP product were risk factors for stroke and death after
more than 12 years of follow-up [16]. Further, a very large
study in subjects undergoing coronary disease assessment
for a variety of clinical indications, including actual cardio-
vascular disease events, found a clear association of cal-
cium, phosphate, and CaP product with the presence of
coronary atherosclerotic disease [19]. Unfortunately,
although these studies included a low proportion of sub-
jects with diabetes, we have not been able to identify any
speciﬁc studies addressing this question in patients with
T2DM. Also, none of these studies included additional
markers of mineral metabolism, such as PTH and 25OHD.
Thus, previous and the current ﬁndings suggest the need
for further research in this speciﬁc area, especially in patients
with diabetes and, in general, in subjects without chronic
kidney disease.
Regarding vitamin D, our results only showed that
subjects with higher 25OHD concentrations (≥30 ng/mL)
had lower cIMT. It should be pointed out that cIMT reﬂects
initial morphologic changes in the intima of the artery wall.
However, the existence of a plaque indicates that the athero-
sclerotic process is established; actually, cardiovascular
events take place due to plaque complications. In our study,
the concentrations of 25OHD were not at all associated with
the presence of carotid plaques. These ﬁndings may indicate
that 25OHD could be a marker of future cardiovascular dis-
ease only in early stages of the atherosclerotic process in dia-
betes. In contrast to the current results, Chen et al. described
the association of lower 25OHD levels and the presence of
carotid plaques in Chinese type 2 diabetic patients [32]. Pre-
vious cross-sectional studies found an association between
lower levels of 25OHD and cIMT [12, 33, 34]. In the large
prospective Framingham Oﬀspring Study, vitamin D deﬁ-
ciency was a predictor of cardiovascular disease only in sub-
jects with hypertension. More importantly, in two meta-
analyses, 25OHD was linked to coronary disease [14] and
cardiovascular and all-cause mortality [11]. Finally, the
Multi-Ethnic Study of Atherosclerosis, a large prospective
Table 3: Multivariable analysis for common carotid intima-media
thickness.
Coeﬃcients Estimate (standard error) p value
Age (years) 0.0047155 (0.0007817) <0.001
Female sex −0.0479803 (0.0150747) 0.002
Dyslipidemia 0.0421709 (0.0150771) 0.006
Vitamin D (20–30) versus
vitamin D< 20 (ng/mL) −0.0189342 (0.0165022) 0.252
Vitamin D≥ 30 versus
vitamin D< 20 (ng/mL) −0.0549896 (0.0240509) 0.023
Adjusted estimates and standard error computed according to multivariable
linear regression model; Multiple R-squared, 0.1778; adjusted R-squared,
0.1627; Kolmogorov-Smirnov test, p value = 0.200.
Table 2: Multivariable analysis for the presence of carotid plaques.
OR (95% CI) p value
Age (years) 1.055 (1.027–1.084) <0.001







PTH (pg/mL) 0.989 (0.974–1.004) 0.151
25OHD (ng/mL) 0.991 (0.965–1.018) 0.530
Adjusted OR and their 95% CI estimated according to multivariable logistic
regression model; Hosmer-Lemeshow test, p value = 0.837.
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cohort study, the authors observed a complete lack of associ-
ation of 25OHD and PTH with baseline cIMT and plaque
prevalence and progression of these markers of subclinical
atherosclerosis at follow-up [15]. It must be pointed out that,
from all these studies, only the one by Carrelli et al. included
also the assessment of circulating calcium and phosphate;
moreover, these authors observed that, apart from 25OHD,
phosphate and CaP product were associated with subclinical
atherosclerosis. Overall, these results give further support to
the accumulating evidence of the role of mineral metabolism
in the atherosclerotic pathogenetic process. However, none
of these factors have been consistently shown to be predictors
of future cardiovascular disease in all the study settings and
populations [11]. We strongly believe that further investiga-
tions are warranted in this ﬁeld. On one hand, we are in need
of further experimental research. On the other hand, clinical
prospective studies are also warranted. Unfortunately, very
few studies have assessed all the main factors (25OHD,
PHT, calcium, phosphate, and FGF-23) involved in the
mineral metabolism pathway together in the same study sub-
jects. The partial information given by a single factor does
not actually provide a whole picture of this potential patho-
genetic pathway contributing to atherosclerosis. We strongly
believe that the assessment of the vitamin D status without
the determination of other parameters of mineral metabo-
lism must be avoided in future studies.
The current study has some limitations. First, this is a
cross-sectional study that was not speciﬁcally designed to
address the associations investigated in the current substudy.
Additionally, this is not a population-based study, and this
may limit the external validity of the current ﬁndings. Never-
theless, the characteristics of the included patients are very
similar to those of the general diabetic population in our
region [35]. The current study has addressed the question
in a large group of well-characterized type 2 diabetic patients
that included extensive work-up on mineral metabolism and
subclinical carotid atherosclerosis (cIMT and plaques).
Although we assessed diﬀerent factors involved in the reg-
ulation of mineral metabolism, we did not assess addi-
tional important molecules that could have extended the
knowledge, such as FGF-23.
5. Conclusions
In conclusion, the current ﬁndings indicate that the CaP
product is associated with established subclinical atheroscle-
rosis in patients with T2DM without previous cardiovascular
disease or chronic kidney disease. Additionally, higher circu-
lating 25OHD concentrations (≥30ng/mL) are associated
with lower cIMT. Given that this was a secondary analysis,
the reported associations need to be conﬁrmed in a prospec-
tively designed study. This new research should include a
comprehensive phenotyping of participants and should not
focus in the study of an isolated factor of mineral metabolism
but rather should assess the wide range of molecules that are
involved in the complex cross-talk between parameters of
mineral metabolism, that is, 25OHD, phosphate, calcium,
PTH, and FGF-23.
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